Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome. That's welcome news.

One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. 24/7 Live Philadelphia Pennsylvania New Jersey Delaware.

CIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy was used to combat these rogue B-cells.